Movement Alert｜Moderna, Inc. Intraday Decline 6.23%, Melanoma Vaccine Data Leak Fallout Continues to Weigh on Sentiment

Market Focus10-26 21:30

On October 26, Moderna, Inc. recorded an Intraday Decline of 6.23% in Regular Trading, trading at $193.07 per share, with turnover of $269 million.

The move aligns with continued market digestion of the leaked phase 3 data tied to the company’s personalized melanoma vaccine program developed with Merck. Circulating figures indicated the therapy reduced cancer recurrence risk by 42% and distant metastasis risk by 38%, below earlier-trial readings of 49% and 59%, reinforcing concern that the eventual full disclosure may not deliver a meaningful upside surprise.

Recent options flow also pointed to a more cautious stance. Bullish call spread positioning has been concentrated around the $210 to $222.5 range, while out-of-the-money $260 calls saw premium-selling activity, suggesting investors are becoming more conservative on near-term upside after the earlier sharp repricing in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment